Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

Background Thyroid cancer is a heterogeneous disease that is classified into differentiated
thyroid carcinoma (DTC), undifferentiated/anaplastic thyroid carcinoma (ATC) and medullary …

Purpose: Retinoic acid (RA) treatment has been used for redifferentiation of metastatic
thyroid cancer with loss of radioiodine uptake. The aim of this study was to improve the …

Aim: The aim of this study was to evaluate the redifferentiative and antiproliferative effects of
rosiglitazone in patients with progressive differentiated thyroid cancer (DTC) without or with …

Although the majority of papillary thyroid carcinoma could be successfully managed by
complete surgical resection alone or resection followed by radioiodine ablation, a small …

甲状腺癌的预后一般较好, 但在核素治疗过程中会有30% 的患者发生失分化,
失分化甲状腺癌由于不能有效摄取131 I 而缺少有效的治疗手段, 其10 年生存率可降至30 …

Çalışmamızın amacı, iyi diferansiye tiroid karsinomunun yaş ve cinsiyetle ilişkisini saptamak,
hastalığın mortalite ve morbiditesini etkileyen risk faktörlerini ve bunların birbirleriyle …

The primary therapy of thyroid cancer is surgical resection. For locally advanced or
metastatic well-differentiated thyroid cancer (DTC), radioactive iodine is often curative. The …

A. Thyroglobulin Patient with thyroid cancer shows high level of thyroglobulin (Tg). There is
close correlation between serum thyroglobulin level and thyroglobulin of tumor. However …

Thyroid cancer originates from epithelial and from parafollicular C-cells. Distant metastases
occur in about 5–10% of patients. RAI therapy and TSH suppressive therapy have an …